Kaplan-Meier analyses identified that patients whose tumors classified into ASCL1 subtype obtained significantly worse OS (P = 0.033) and DFS (P = 0.017) compared to those patients whose tumors with dominant markers of NEUROD1, POU2F3, or YAP1 (Supplementary Figure 1), which suggested that molecular subtype classification based on transcriptome data may serve as a predictor for survival outcome in primary SCLC tumors. Here, POU2F3 is linked to small cell lung carcinoma.